肝硬化再代偿的临床特征、影响因素及其预测效能分析
Clinical Features, Influencing Factors and Predictive Efficacy Analysis of Decompensated Cirrhosis
DOI: 10.12677/acm.2026.1641350, PDF,    科研立项经费支持
作者: 汪泽清, 王 鑫, 宋育林*:安徽医科大学第一附属医院消化内科,安徽 合肥
关键词: 肝硬化肝硬化失代偿期再代偿影响因素预测Liver Cirrhosis Decompensated Liver Cirrhosis Recompensation Influencing Factors Prediction
摘要: 目的:分析肝硬化失代偿期患者发生再代偿的临床特征及影响再代偿发生的相关因素并分析预测效能。方法:回顾性纳入2018年~2023年初次确诊的失代偿期肝硬化住院患者120例,根据再代偿情况,分为再代偿组53例和持续失代偿组67例。收集两组人口学资料、实验室指标、影像学结果、内镜结果及合并症情况,计算临床评分,其中包括终末期肝病模型评分(MELD评分)、Child-Pugh评分、FIB-4指数、谷草转氨酶/血小板比值指数(APRI)、King评分、Lok评分和白蛋白–胆红素评分(ALBI)。采用方差膨胀因子(VIF)诊断变量多重共线性,结合单因素分析筛选变量,通过二元Logistic回归分析肝硬化失代偿期患者发生再代偿的影响因素,采用受试者工作特征(ROC)曲线评价预测效能并分析其预测效能。结果:再代偿组患者年龄、天冬氨酸氨基转移酶(AST)、直接胆红素(DBil)、肌酐(Scr)、MELD评分、Child-Pugh分级、FIB-4指数、King评分、Lok评分、白蛋白–胆红素评分(ALBI)低于持续失代偿组(P < 0.05);再代偿组患者血红细胞、白蛋白、丙氨酸氨基转移酶(ALT)、血钙和甲胎蛋白高于持续失代偿组(P < 0.05)。经共线性诊断显示ALBI、Lok评分与白蛋白、Child-Pugh评分存在强共线性(VIF > 5),二元Logistic回归分析显示,白蛋白、ALT、AST、Child-Pugh评分、MELD评分是影响患者实现再代偿的独立因素(P均<0.05);ALBI、Lok评分因强共线性出现回归系数方向异常,该异常结果具有统计学与临床探讨价值,予以保留并深入分析。ROC曲线结果分析显示,白蛋白、ALT、AST、Child-Pugh评分、MELD评分值联合预测,AUC提高至0.832 (95% CI: 0.761~0.903),此时模型灵敏度为0.925、特异性0.642。结论:白蛋白、ALT、AST、Child-Pugh评分、MELD评分值是肝硬化失代偿期患者发生再代偿的独立影响因素;联合白蛋白、ALT、AST、Child-Pugh评分、MELD评分值为预测肝硬化失代偿期患者再代偿发生提供了新的证据。
Abstract: Objective: To analyze the clinical characteristics of decompensated cirrhosis patients undergoing recompensation, investigate the factors influencing recompensation, and analyse the predictive efficacy of the related factors. Methods: A retrospective study was conducted on 120 hospitalized patients with decompensated cirrhosis diagnosed for the first time between 2018 and early 2023. Based on recompensation status, the patients were divided into a recompensation group (n = 53) and a persistent decompensation group (n = 67). Demographic data, laboratory parameters, imaging findings, endoscopic results, and comorbidities were collected from both groups. Clinical scores, including the end-stage liver disease model score (MELD score), Child-Pugh score, FIB-4 index, aspartate aminotransferase/platelet ratio index (APRI), King score, Lok score, and albumin-bilirubin index (ALBI), were calculated. The variance inflation factor (VIF) was used to diagnose multicollinearity of variables, and single factor analysis was employed to screen variables. Binary Logistic regression analysis was conducted to investigate the influencing factors of decompensated cirrhosis patients’ recompensation. Receiver operating characteristic (ROC) curves were used to evaluate predictive performance, and a predictive model was constructed. Results: The recompensation group exhibited lower levels of age, aspartate aminotransferase (AST), direct bilirubin (DBil), creatinine (Scr), MELD score, Child-Pugh grade, FIB-4 index, King score, Lok score, and ALBI compared to the persistent decompensation group (P < 0.05). The recompensation group also showed higher levels of hemoglobin, albumin, alanine aminotransferase (ALT), serum calcium ions, and alpha-fetoprotein than the persistent decompensation group (P < 0.05). Collinearity diagnosis showed strong collinearity between ALBI, Lok score and albumin, Child-Pugh score (VIF > 5). Binary Logistic regression analysis revealed that albumin, ALT, AST, Child-Pugh score, and MELD score were independent factors influencing patients’ achievement of recompensation (all P < 0.05). that albumin, ALT, AST, Child-Pugh score and MELD score were independent factors influencing recompensation (all P < 0.05). The abnormal direction of regression coefficients of ALBI and Lok score was caused by strong collinearity, which was of statistical and clinical significance and retained for in-depth analysis. ROC curve analysis revealed that the combined prediction of albumin, ALT, AST, Child-Pugh score, MELD score increased the AUC to 0.832 (95% CI: 0.761~0.903), with a model sensitivity of 0.925 and specificity of 0.642. Conclusion: Albumin, ALT, AST, Child-Pugh score and MELD score are independent factors for recompensation in patients with decompensated cirrhosis. The combined model of these indicators provides new evidence for predicting recompensation in decompensated cirrhosis patients.
文章引用:汪泽清, 王鑫, 宋育林. 肝硬化再代偿的临床特征、影响因素及其预测效能分析[J]. 临床医学进展, 2026, 16(4): 1165-1176. https://doi.org/10.12677/acm.2026.1641350

参考文献

[1] Bhardwaj, A., Jindal, A., Arora, V., Rajan, V., Bhadoria, A.S., Kumar, G., et al. (2018) Natural History of Patients with Compensated Cirrhosis and a Hepatic Venous Pressure Gradient > 20 mmHg: A Prospective Longitudinal Cohort Study. Journal of Hepatology, 68, S716-S717. [Google Scholar] [CrossRef
[2] 徐京杭, 于岩岩, 徐小元. 肝硬化逆转及再代偿相关研究进展[J]. 中华肝脏病杂志, 2023, 31(7): 673-676.
[3] Liaw, Y.F., Sheen, I.S., Lee, C.M., Akarca, U.S., Papatheodoridis, G.V., Wong, F.S., et al. (2011) Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF, and Entecavir in Patients with Decompensated Chronic Hepatitis B Liver Disease. Hepatology, 53, 62-72. [Google Scholar] [CrossRef] [PubMed]
[4] Cheung, M.C.M., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., et al. (2016) Outcomes after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C and Decompensated Cirrhosis. Journal of Hepatology, 65, 741-747. [Google Scholar] [CrossRef] [PubMed]
[5] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669.
[6] Kim, T.H., Um, S.H., Lee, Y., Yim, S.Y., Jung, Y.K., Seo, Y.S., et al. (2021) Determinants of Re‐Compensation in Patients with Hepatitis B Virus‐Related Decompensated Cirrhosis Starting Antiviral Therapy. Alimentary Pharmacology & Therapeutics, 55, 83-96. [Google Scholar] [CrossRef] [PubMed]
[7] Premkumar, M., et al. (2023) Recompensation of Chronic Hepatitis c-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Real-World Data from the Punjab HCV Elimination Model. Hepatology, 78, S10-S11.
[8] 中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019, 27(11): 846-865.
[9] 王柏凯, 徐莹, 俞骁珺, 等. 十一种临床评分预测肝硬化伴急性上消化道出血6周死亡风险[J]. 胃肠病学和肝病学杂志, 2023, 32(3): 282-288.
[10] Villanueva, C., Albillos, A., Genescà, J., Abraldes, J.G., Calleja, J.L., Aracil, C., et al. (2015) Development of Hyperdynamic Circulation and Response to β‐Blockers in Compensated Cirrhosis with Portal Hypertension. Hepatology, 63, 197-206. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, Y., Liu, X., Li, S., Lin, C., Ye, Q., Wang, Y., et al. (2023) Risk of HCC Decreases in HBV-Related Patients with Cirrhosis Acquired Recompensation: A Retrospective Study Based on Baveno VII Criteria. Hepatology Communications, 8, e0355. [Google Scholar] [CrossRef] [PubMed]
[12] Goh, X.E., Goh, M.X., Chen, V.L., Garcia-Tsao, G., Abraldes, J.G. and Wong, Y.J. (2026) Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 24, 911-922. [Google Scholar] [CrossRef] [PubMed]
[13] 许丹青, 张映媛, 木唤, 等. 失代偿期乙型肝炎肝硬化患者再代偿的影响因素分析[J]. 临床肝胆病杂志, 2025, 41(7): 1364-1370.
[14] 阮佳佳, 温世飞, 王霞, 等. 首次失代偿期乙型肝炎肝硬化患者获得再代偿的影响因素分析[J]. 临床肝胆病杂志, 2022, 38(8): 1796-1800.
[15] Chen, Y., Wen, H., Li, Y., Zhang, W., Mao, T., Jiang, C., et al. (2025) Recompensation in Patients with Autoimmune Hepatitis-Related Decompensated Cirrhosis Following Immunosuppressive Therapy. JHEP Reports, 7, Article ID: 101496. [Google Scholar] [CrossRef] [PubMed]
[16] 朱宁宁, 焦淑宁, 张域爽, 等. 乙型肝炎肝硬化失代偿期患者再代偿的影响因素及其预测效能分析[J]. 山东医药, 2025, 65(6): 67-72.
[17] 王菁菁, 刘丽改, 谢雯. 白蛋白生理功能再认识[J]. 临床肝胆病杂志, 2025, 41(3): 404-408.
[18] Chang, M., Cheng, J., Chien, R. and Liaw, Y. (2020) Hepatitis Flares Are Associated with Better Outcomes than No Flare in Patients with Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 18, 2064-2072.e2. [Google Scholar] [CrossRef] [PubMed]
[19] Ampuero, J., Lucena, A., Berenguer, M., Hernández-Guerra, M., Molina, E., Gómez-Camarero, J., et al. (2024) Predictive Factors for Decompensating Events in Patients with Cirrhosis with Primary Biliary Cholangitis under Different Lines of Therapy. Hepatology, 80, 791-806. [Google Scholar] [CrossRef] [PubMed]
[20] 高国全, 汤其群. 生物化学与分子生物学[M]. 第10版. 北京: 人民卫生出版社, 2024: 182-186.
[21] 张兴, 胡洋洋, 罗越, 等. 线粒体DNA在慢性肝病发病机制中作用的研究进展[J]. 中华肝脏病杂志, 2022, 30(4): 447-451.
[22] 希古日干, 苏雅, 佟静, 等. 终末期肝病模型(MELD)评分在终末期肝病中的应用[J]. 临床肝胆病杂志, 2025, 41(3): 556-560.
[23] Hofer, B.S., Simbrunner, B., Hartl, L., Jachs, M., Balcar, L., Paternostro, R., et al. (2023) Hepatic Recompensation According to Baveno VII Criteria Is Linked to a Significant Survival Benefit in Decompensated Alcohol‐Related Cirrhosis. Liver International, 43, 2220-2231. [Google Scholar] [CrossRef] [PubMed]
[24] Peng, Y., Qi, X. and Guo, X. (2016) Child-Pugh versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. Medicine, 95, e2877. [Google Scholar] [CrossRef] [PubMed]
[25] 万学红, 卢雪峰. 诊断学[M]. 第10版. 北京: 人民卫生出版社, 2024: 275.
[26] 杨志慧, 陈美娟, 张濛销, 等. 多维度肝功能评估预测肝硬化再代偿研究进展[J]. 临床军医杂志, 2026, 54(2): 111-114.
[27] Xavier, S.A., Vilas-Boas, R., Boal Carvalho, P., Magalhães, J.T., Marinho, C.M. and Cotter, J.B. (2018) Assessment of Prognostic Performance of Albumin-Bilirubin, Child-Pugh, and Model for End-Stage Liver Disease Scores in Patients with Liver Cirrhosis Complicated with Acute Upper Gastrointestinal Bleeding. European Journal of Gastroenterology & Hepatology, 30, 652-658. [Google Scholar] [CrossRef] [PubMed]
[28] Liu, Y., Wu, S., Cai, S. and Xie, B. (2024) The Prognostic Evaluation of ALBI Score in Endoscopic Treatment of Esophagogastric Varices Hemorrhage in Liver Cirrhosis. Scientific Reports, 14, Article No. 780. [Google Scholar] [CrossRef] [PubMed]